SS-31

If your provider determines you are not a candidate for any available treatment, any consultation fee paid will be refunded within 7–10 business days. You are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.

SS-31 is studied for interaction with cardiolipin, a phospholipid in the inner mitochondrial membrane. That makes the research thesis structural and membrane-specific rather than a general antioxidant claim. It does not establish a clinical outcome for the compounded preparation offered here.

Elamipretide is FDA-approved as FORZINITY to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. The preparation offered here is compounded for a different purpose and is not FORZINITY or a substitute for it. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.²

No. FORZINITY is a specific FDA-approved finished drug product containing elamipretide for a narrow Barth syndrome indication. The preparation offered here is compounded to an individual prescription for a different purpose. The active molecule may be the same, but the finished products are not interchangeable, and FORZINITY studies do not establish what this compounded preparation will do.

FORZINITY was evaluated in a 12-patient randomized, double-blind, placebo-controlled crossover trial in Barth syndrome. It was not superior to placebo on the primary six-minute-walk or fatigue endpoints. Increased knee extensor strength was observed during the extension period, and FDA used that intermediate endpoint for accelerated approval while requiring a confirmatory trial. Those findings belong to FORZINITY and its studied population, not this compounded preparation.² Larger trials in primary mitochondrial myopathy also missed their primary endpoints.

SS-31 is the opposite of a molecule that benefits from vague marketing. It has a specific molecular target, an FDA-approved finished product with a narrow indication, negative trial results that matter, and a compounded preparation that is not interchangeable with that approved product. That is exactly the kind of record that deserves clinical interpretation. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.^F4 Testing has found wide variation in purity and in how much of the compound is actually in the vial. With AnthologyRX, a licensed provider reviews the whole record and a licensed US pharmacy fills your individual prescription if treatment is appropriate. The sophistication is in knowing what the molecule is, what the evidence says, and what it does not let us claim.